Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Zanolimumab (Synonyms: Anti-Human CD4 Recombinant Antibody)

Catalog No. T80744 Copy Product Info
🥰Excellent
Zanolimumab is a humanised monoclonal antibody targeting CD4, exhibiting cytotoxic and antiproliferative properties. By binding to the CD4 molecule and blocking T cell receptor (TCR) signalling, it is used in the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and T-cell lymphoma.

Zanolimumab

Copy Product Info
🥰Excellent
Catalog No. T80744
Synonyms Anti-Human CD4 Recombinant Antibody

Zanolimumab is a humanised monoclonal antibody targeting CD4, exhibiting cytotoxic and antiproliferative properties. By binding to the CD4 molecule and blocking T cell receptor (TCR) signalling, it is used in the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and T-cell lymphoma.

Zanolimumab
Cas No. 652153-01-0
TargetMol | Customer service
Customer service consultation
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$247-In Stock
5 mg$619-In Stock
10 mg$993-In Stock
25 mg$1,470-In Stock
50 mg$1,980-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:97.2% (SDS-PAGE); 97.1% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Zanolimumab is a humanised monoclonal antibody targeting CD4, exhibiting cytotoxic and antiproliferative properties. By binding to the CD4 molecule and blocking T cell receptor (TCR) signalling, it is used in the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and T-cell lymphoma.
In vitro
Methods:
To evaluate the ability of Zanolimumab to induce antibody-dependent cell-mediated cytotoxicity (ADCC) via natural killer (NK) cells, we conducted in vitro cytotoxicity assays using NK cells as effector cells and CD4⁺ T cells as target cells.
Results:
We found that Zanolimumab was highly effective in promoting the killing of CD4⁺ T cells, inducing significant specific lysis at a concentration of 10 ng/mL. Moreover, at both 10 and 100 ng/mL, Zanolimumab showed a stronger cytotoxic effect on the CD45RO⁺ subset than on the CD45RA⁺ subset.[1]
SynonymsAnti-Human CD4 Recombinant Antibody
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetCD4/LEU3
Chemical Properties
Molecular Weight143.81 kDa
Cas No.652153-01-0
Antibody Information
IsotypeHuman IgG1 kappa
Recommended Isotype Control
Storage & Solubility Information
Storage-20°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Citations

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Zanolimumab | purchase Zanolimumab | Zanolimumab cost | order Zanolimumab | Zanolimumab in vitro | Zanolimumab molecular weight